Blog Coverage La Jolla’s Lead Product Candidate LJPC-501 Posts Positive Phase-III Trial Results

Upcoming AWS Coverage on Sage Therapeutics Post-Earnings Results

LONDON, UK / ACCESSWIRE / February 28, 2017 / Active Wall St. blog coverage looks at the headline from La Jolla Pharmaceutical Co. (NASDAQ: LJPC) as the Company announced on February 27, 2017, positive results from the Phase-3 study of LJPC-501 in patients with catecholamine resistant hypotension (CRH). Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of La Jolla Pharma’s competitors within the Biotechnology space, Sage Therapeutics, Inc. (NASDAQ: SAGE), reported on February 23, 2017, its business highlights and financial results for Q4 and full year ended December 31, 2016. AWS will be initiating a research report on Sage Therapeutics in the coming days.

Today, AWS is promoting its blog coverage on LJPC; touching on SAGE. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

ATHOS-3 Study

The ATHOS-3 (Angiotensin II for the Treatment of High-Output Shock) trial was designed as a multicenter, randomized, double-blind, placebo-controlled, Phase-3 clinical study to test La Jolla’s lead product LJPC-501 in patients with CRH. A total of 344 patients were randomized across nine countries, 321 of whom received study treatment. Patients were randomized 1:1 to receive either LJPC-501 or placebo on a background of standard-of-care vasopressors selected by the investigators. Randomized patients received their assigned treatment via continuous intravenous infusion.

The primary efficacy endpoint was the percentage of patients with a mean arterial pressure (MAP) ≥ 75 mmHg or a 10 mmHg increase from baseline MAP at 3 hours following the initiation of study treatment without an increase in standard-of-care vasopressors. ATHOS-3 was conducted under a Special Protocol Assessment (SPA) agreed with the US Food and Drug Administration (FDA) in 2015. The SPA stipulates that a study of this size and design could provide sufficient safety and efficacy signals and an adequate evaluation of the risk/benefit to the patients to support FDA review and consideration for marketing approval.

Data from the ATHOS- 3 study demonstrated that the percentage of patients achieving a pre-specified target blood pressure response was highly statistically significant: 23% of the 158 placebo-treated patients had a blood pressure response compared to 70% of the 163 LJPC-501-treated patients. On the downside, LJPC-501 treated patients showed a 22% reduction in mortality risk through day 28.

Throughout the study, safety outcomes were followed by an independent Data Safety Monitoring Board (DSMB). The DSMB recommended that the study continue as originally planned. In collaboration with the investigators, La Jolla plans to present and publish detailed results from the ATHOS-3 study later this year.

“We are grateful to the patients, their families, and the dedicated medical teams who contributed to this successful study,” said George F. Tidmarsh, M.D., Ph.D., President and Chief Executive Officer of La Jolla, “We also are very appreciative of the FDA’s advice and contributions in the development of LJPC-501 and look forward to meeting with the FDA to discuss our NDA submission planned for the second half of this year.”

About LJPC-501

LJPC-501 is La Jolla’s proprietary formulation of synthetic human angiotensin II. Angiotensin II, the major bioactive component of the renin-angiotensin system, serves as one of the body’s central regulators of blood pressure. LJPC-501 is being developed for the treatment of patients with catecholamine resistant hypotension (CRH). LJPC-501 is the first synthetic human angiotensin II product candidate to be tested in a Phase-3 study.

What is Catecholamine Resistant Hypotension?

CRH is a life-threatening condition in patients with distributive shock (dangerously low blood pressure with adequate cardiac function) in which blood does not properly flow to vital organs. As per the press release, there are approximately 500,000 distributive shock cases in the United States per year, an estimated 200,000 of which develop CRH. More than 50% of CRH patients die within 30 days.

Stock Performance

At the closing bell, on Monday, February 27, 2017, following the announcement, La Jolla Pharma’s stock skyrocketed 76.75%, ending the trading session at $35.12. A total volume of 18.28 million shares were traded at the end of the day, which was higher than the 3-month average volume of 146.21 thousand shares. In the last six months and previous twelve months, shares of the Company have rallied 106.10% and 121.30%, respectively. Moreover, the stock soared 100.34% since the start of the year. The stock currently has a market cap of $604.45 million.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 456180